Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
This is a phase I, open label, dose escalation study to evaluate tolerability, safety , pharmacokinetics and efficacy in patients with KRAS mutant NSCLC by using HL-085 and Docetaxel.
Nsclc
DRUG: HL-085|DRUG: Docetaxel
Number of Adverse Events (AEs), Number of Treatment-Related Adverse Events as Assessed by CTCAE v4.03 will be counted., Duration of the study, estimated to be approximately 24 months|Maximum tolerated dose (MTD), The dose level immediately below the dose level at which more than 2 patients from a cohort of 3 to 6 patients experience a dose-limiting toxicity (DLT), DLTs within the first cycle of therapy (up to 35 days)
Overall response rate (ORR), ORR is the proportion of patients with a best overall response of complete response (CR) or partial response (PR), as assessed per response evaluation criteria in solid tumors (RECIST) v1.1., Duration of the study, estimated to be approximately 24 months|Peak Plasma Concentration (Cmax), Cmax is the maximum plasma concentration of HL-085 or metabolite(s)., Duration of the study, estimated to be approximately 24 months|Area under the plasma concentration verus time curve(AUC), AUC of HL-085 or metabolites(s) after repeated dosing, Duration of the study, estimated to be approximately 24 months
This is a phase I, open label, dose escalation study to evaluate tolerability, safety , pharmacokinetics and efficacy in patients with KRAS mutant NSCLC by using HL-085 and Docetaxel.